Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
45.04
-1.48 (-3.18%)
Nov 20, 2024, 4:00 PM EST - Market closed
Apogee Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
91
Market Cap
2.56B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAPGE News
- 3 days ago - Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 - GlobeNewsWire
- 11 days ago - Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis - Seeking Alpha
- 17 days ago - Apogee Therapeutics to Participate in Upcoming November Investor Conferences - GlobeNewsWire
- 5 weeks ago - Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting - GlobeNewsWire
- 2 months ago - Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit - GlobeNewsWire
- 2 months ago - Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer - GlobeNewsWire
- 3 months ago - Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases - GlobeNewsWire
- 3 months ago - Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results - GlobeNewsWire